Background: Global cancer statistics indicate colorectal cancer as the second leading cause of cancer-related deaths, with rectal cancer accounting for approximately 30% of cases. Despite neoadjuvant ...

Rectal cancer is one of the most common causes of cancer deaths in the western world. Individuals diagnosed with rectal cancer are mainly treated with surgery. However, the risk remains that rectal ...

Thousands of women who undergo radiotherapy for low-risk breast cancer could be spared some of the side effects of treatment after a study confirmed that more targeted treatments are just as ...

To investigate rectal hydrogel spacer use, placement complications, and associated radiation delays in the United States.The MerativeTM MarketScan Database was used to identify prostate cancer ...

The Conventional versus Hypofractionated High-dose Intensity-modulated Radiotherapy for Prostate Cancer (CHHiP) trial, published in 2016, showed that among more than 3000 patients with localized ...

Background Endoscopic intermuscular dissection (EID) is a promising new technique for managing rectal deep submucosal invasive cancer (D-SMIC), but long-term outcome data are currently lacking.

Total neoadjuvant therapy (TNT) is recommended for locally advanced rectal cancer (LARC) with high-risk factors. The objective of this multi-center phase 2 study is to evaluate the impact of a newly ...

The ShorTrip trial found that short-course radiotherapy followed by FOLFOX and FOLFOXIRI improved pathological response rates in locally advanced rectal cancer.

3593Background: Variation in response to radiotherapy for the treatment of rectal cancer is likely due to heterogeneity in the tumour microenvironment. However, to date, no reliable predictive ...

The Trade-Off The standard of care for resectable locally advanced rectal cancer has been neoadjuvant radiation and chemotherapy followed by surgery for resectable locally advanced rectal cancers.